PuSH - Publikationsserver des Helmholtz Zentrums München

Köhnke, T.* ; Sauter, D.* ; Ringel, K.* ; Hoster, E.* ; Laubender, R.P.* ; Hubmann, M.* ; Bohlander, S.K.* ; Kakadia, P.M.* ; Schneider, S. ; Dufour, A.* ; Sauerland, M.C.* ; Berdel, W.E.* ; Büchner, T.* ; Wörmann, B.* ; Braess, J.* ; Hiddemann, W. ; Spiekermann, K. ; Subklewe, M.

Early assessment of minimal residual disease in aml by flow cytometry during aplasia identifies patients at increased risk of relapse.

Leukemia 29, 377-386 (2015)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
In acute myeloid leukemia (AML), assessment of minimal residual disease (MRD) by flow cytometry (flow MRD) after induction and consolidation therapy has been shown to provide independent prognostic information. However, data on the value of earlier flow MRD assessment is lacking. Therefore, the value of flow MRD detection was determined during aplasia in 178 patients achieving complete remission after treatment according to AMLCG induction protocols. Flow MRD-positivity during aplasia predicted poor outcome (5-year relapse-free survival (RFS) 16% vs 43%, P<0.001) independently from age and cytogenetic risk group (hazard ratio for MRD-positivity 1.71; P=0.009). Importantly, the prognosis of patients without detectable MRD was not impacted by morphological blast count during aplasia nor by MRD status post-induction. Early flow MRD was also evaluated in the context of existing risk factors. Flow MRD was prognostic within the intermediate cytogenetic risk group (5-year RFS 15% vs. 37%, p=0.016) as well as for patients with normal karyotype and NPM1 mutations (5-year RFS 13% vs. 49%, P=0.02) or FLT3-ITD (3-year RFS rates 9% vs. 44%, P=0.016). Early flow MRD assessment can improve current risk stratification approaches by prediction of RFS in AML and might facilitate adaptation of post-remission therapy for patients at high risk of relapse.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Acute Myeloid-leukemia; High-dose Cytarabine; European Leukemianet; Cell Transplantation; Unselected Patients; Treatment Response; Complete Remission; Induction Therapy; Cooperative Group; Normal Karyotype
ISSN (print) / ISBN 0887-6924
e-ISSN 1476-5551
Zeitschrift Leukemia
Quellenangaben Band: 29, Heft: 2, Seiten: 377-386 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) CCG Pathogenesis of Acute Myeloid Leukemia (KKG-KPL)
CCG Hematopoetic Cell Transplants (IMI-KHZ)
Institute of Stem Cell Research (ISF)